title: The pre-BCR to the rescue: therapeutic targeting of pre-B cell ALL.
abstract: Pre B-ALL is an aggressive cancer of the blood for which treatment of patients with relapsed and refractory disease remains a challenge. In this issue of Cancer Cell, Geng and colleagues surveyed the activation status of the pre-B cell receptor and comprehensively investigated downstream signaling mechanisms currently targetable with small molecule inhibitors.
authors.affiliation: Department of Pathology and Howard Hughes Medical Institute, NYU School of Medicine New York, NY 10016, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Trimarchi
authors.affiliation: Department of Pathology and Howard Hughes Medical Institute, NYU School of Medicine New York, NY 10016, USA. Electronic address: iannis.aifantis@nyumc.org.
authors.forename: Iannis
authors.initials: I
authors.lastname: Aifantis
mesh_terms: D004268:DNA-Binding Proteins / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism*; D054448:Precursor Cells, B-Lymphoid / Q000378:metabolism*; D051560:Proto-Oncogene Proteins c-bcl-6
chemical_list: C084103:BCL6 protein, human; D004268:DNA-Binding Proteins; D051560:Proto-Oncogene Proteins c-bcl-6